EZH2 inhibition is an effective therapeutic strategy in epithelioid sarcomas that have a loss of SMARCB1, a subunit of SWI/SNF complex that opposes the activity of EZH215. This evidence concerns the gene SMARCB1 and epithelioid sarcoma.